sumatriptan intranasal
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
September 06, 2023
Tonix Pharmaceuticals Announces Commitment to Supply Tosymra (sumatriptan Nasal Spray) 10 mg for Treatment of Acute Migraine to Meet Potential Increased Demand Following GSK’s Planned Discontinuation of Imitrex (sumatriptan) Nasal Spray After January 2024
(GlobeNewswire)
- "Tonix Pharmaceuticals Holding Corp...announced that it is committed to meeting potential increased demand for Tosymra
®
(sumatriptan) nasal spray 10 mg after GlaxoSmithKline’s (GSK) planned discontinuation of Imitrex (sumatriptan) nasal spray 5 mg and 20 mg products after January, 2024....On August 8, 2023, GSK informed the U.S. Food and Drug Administration (FDA) of its plan to discontinue Imitrex nasal spray 5 mg and 20 mg doses after January 31, 2024....Tonix is preparing for potential increased demand for Tosymra (sumatriptan nasal spray) 10 mg to help avoid possible drug shortages for patients who suffer from migraines. Tosymra nasal spray is approved on the basis of bioequivalence to Imitrex injection 4 mg."
Commercial • Discontinued • CNS Disorders • Migraine • Pain
July 23, 2022
Feasibility, Utility, and Interrater Reliability of the Cluster Headache Severity Scale, Cluster Headache Quality of Life, Cluster Headache Index, and 6-Item Headache Impact Test in Pediatric Cluster Headache.
(PubMed, J Child Neurol)
- "All children responded to prednisolone as bridging therapy and 23 of 32 showed adequate pain relief after sumatriptan nasal spray for an acute attack... Majority of pediatric cluster headache patients are likely to respond to prednisolone and sumatriptan. Cluster Headache Severity Scale, Cluster Headache Quality of Life, and Headache Impact Test-6 can be used for pediatric cluster headache patients for treatment monitoring."
HEOR • Journal • Pain • Pediatrics
May 29, 2020
Drugs for Acute Attack of Pediatric Migraine: A Network Meta-analysis of Randomized Controlled Trials.
(PubMed, Clin Neurol Neurosurg)
- "We found that sumatriptan nasal spray and zolmitriptan nasal spray were superior to placebo in the two efficacy outcomes, whereas almotriptan, rizatriptan, sumatriptan with naproxen sodium, ibuprofen and ibuprofen suspension were superior to placebo only in one of the efficacy outcomes. And the most effective treatment to achieve pain-free is sumatriptan with naproxen sodium. Ibuprofen and ibuprofen suspension were the most effective treatments to achieve pain-relief."
Journal • Retrospective data • Review • CNS Disorders • Migraine • Pain • Pediatrics
August 26, 2019
Efficacy of triptans for the treatment of acute migraines: a quantitative comparison based on the dose-effect and time-course characteristics.
(PubMed, Eur J Clin Pharmacol)
- "This study evaluated the efficacy characteristics of seven kinds of triptans and their different dosage forms. The present findings provide necessary quantitative information for migraine medication guidelines."
Clinical • Journal
December 27, 2019
Development and evaluation of in-situ nasal gel formulations of nanosized transferosomal sumatriptan: Design, optimization, in vitro and in vivo evaluation
(Dovepress)
- "Pharmacokinetic evaluation showed that the prepared in-situ gel of SUT [Sumatriptan succinate]-loaded nano-transferosomes gave enhanced bioavailability, 4.09-fold, as compared to oral drug solution.... Based on enhancing the bioavailability and sustaining the drug release, it can be concluded that the in-situ gel of SUT-loaded nano-transferosomes were developed as a promising non-invasive drug delivery system for treating migraine."
Clinical data
January 06, 2019
Therapeutic Effects of Intranasal Sumatriptan for Cluster Headache
(PubMed, Yakugaku Zasshi)
- "Oxygen inhalation and/or subcutaneous injection were effective for nonresponsive cases. Therefore, these factors are considered to be useful for predicting therapy before applying sumatriptan nasal spray."
Journal
1 to 6
Of
6
Go to page
1